Overview

A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants

Status:
COMPLETED

Trial end date:
2024-08-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the drug-drug interaction (DDI) potential of coadministration of itraconazole or rifampin on the single dose drug levels of golcadomide.

Phase:

PHASE1

Details

Lead Sponsor:

Celgene

Treatments:

Itraconazole
Rifampin